ZUG, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Executive Committee and Board of Directors.
Attachment
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
| Source: Oculis Holding AG
Attachments
Recommended Reading
-
Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated...
Read More -
Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated...
Read More